Chemotherapy is an integral part of the present cancer treatment paradigm, despite its common and severe side effects. Nanotechnology provides a plethora of promising avenues for overcoming chemotherapy limitations. Drug encapsulation within nanoparticles helps to retain it in a patient’s body for an extended period, increasing the possibility of it reaching cancer cells. Furthermore, nanoparticles help to decrease some of the ill side effects of chemo by changing the way the drug distributes throughout the body. These considerations led to the creation of the first FDA-approved drug-carrying nanoparticles for cancer treatment: Doxil® or Caelex®, DaunoXome® and Abraxane®. While these nanomedicines have been able to decrease some of the common chemo side effects, drug encapsulation into a nanoparticle did not lead to the impressive improvements in treatment outcomes and many researchers believe that nanomedicine efficacy can be improved even further.

In this review, we highlighted major barriers within the human body that prevent nanoparticles from reaching cancer cells (Fig. 1).  Briefly, once a nanoparticle enters the bloodstream, it is instantly being attacked by the immune cells that recognize it as a foreign object. This results in the majority of the particles being entrapped in the liver and spleen, with only a small percentage left in circulation. Furthermore, even the particles that escaped from the immune system and reached the tumor site need to overcome several local barriers, posed by the abnormal tumor physiology.

Encouraging breakthroughs, however, have been made in the last few years towards the development of new classes of nanoparticles that can respond to the tumor-specific conditions and successfully deliver therapeutics to cancer cells. Concurrently, there is an increasing number of reports describing the use of ‘priming’ strategies that target one or several tumor microenvironment components to enhance the delivery and efficacy of nanomedicines. For example, radiation therapy is often used in the clinic in combination with chemotherapy. Knowing how exactly radiation influences tumor microenvironment can help with the development of optimal combination regimes that will make treatment more effective. Similarly, photodynamic therapy, which relies on the use of a light-activatable molecule and light to kill cancer cells, can be used to make tumors more amenable for nanoparticle accumulation.

This review discusses recent advances in cancer nanomedicine exploiting both nanoparticle design and tumor microenvironment modification (Fig. 2) and provide a critical perspective on the future development of nanomedicine delivery in oncology.

Marta Overchuk ¹, Gang Zheng ^1,2,3
1Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, ON, Canada
²Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
³Department of Medical Biophysics, University of Toronto, Canada

Publication

Read offline:     

Related Articles:

	Could mometasone furoate be a viable glucocorticoid… Glucocorticoids are medications widely used to treat inflammation and allergies, and in contexts of immunosuppression such as after transplants. They are well-established and safe. The problem is that, when used…
	Defects in mismatch repair increase cancer risk and… Microsatellites are formed by 1-6 nucleotide base pairs that are repeated in direct order 5-50 times. Repetitive DNA including microsatellites are mainly present in non-coding DNA regions that occupy more…
	Unlocking new treatments for bone diseases: using… Despite appearances, bones are a constantly changing organ in the body. Cells that produce new bone (named osteoblasts) and cells that break down bone (named osteoclasts) work in harmony to…
	Your pharmacist will see you now! Public perception of pharmacists might be limited to dispensing medications. However, pharmacists are trained to deliver patient care to help patients improve their health-related outcomes and achieve their goals. Recognizing…
	Lipid nanoparticles loaded with CpG oligonucleotides… Since the emergence of immune checkpoint inhibitors (ICIs), cancer immunotherapy has dramatically developed. However, its drawback is the low overall response rate to its therapeutic effect. The efficacy of immunotherapy…
	Muscle pain treated with injected normal saline solution Pain comes in all shapes and sizes. Ranging from acute to chronic, from nociceptive and myofascial to neuropathic, pain is a part of life. Myofascial or muscle pain, is among…